Hanumaiah Telikepalli

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 270 citations

Pdgfra Variants, Oncogenic Agent, Medicine +9

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Wayne W. Chan, Scott Wise, Michael D. Kaufman et al. · Cancer Cell · 2011 · 204 citations · Full text

Switch-control Inhibitor Dcc-2036, Signal Transduction, Signaling Pathway +9

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

James R. Henry, Michael D. Kaufman, Sheng-Bin Peng et al. · Journal of Medicinal Chemistry · 2015 · 84 citations · Full text

Kinase Inhibitors, Pharmaceutical Chemistry, Tumor Biology +20

Antitubercular Natural Products:  Berberine from the Roots of Commercial <i>Hydrastis </i><i>c</i><i>anadensis </i>Powder. Isolation of Inactive 8-Oxotetrahydrothalifendine, Canadine, β-Hydrastine, and Two New Quinic Acid Esters, Hycandinic Acid Esters-1 and -2

Elmer J. Gentry, Hanuman B. Jampani, Ali Keshavarz-Shokri et al. · Journal of Natural Products · 1998 · 78 citations

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Bryan D. Smith, Michael D. Kaufman, Cynthia B. Leary et al. · Molecular Cancer Therapeutics · 2015 · 75 citations

Switch Control Pocket, Glioma, Tumor Biology +16